Treatment options with recombinant leptin in various types of lipodystrophy.

[1] Rodriguez A.J., Mastronardi C.A., Paz-Filho G.J.: New advances in the treatment of generalized lipodystrophy: Role of metreleptin. Ther. Clin. Risk Manag., 2015; 11: 1391–1400 RodriguezA.J. MastronardiC.A. Paz-FilhoG.J. New advances in the treatment of generalized lipodystrophy: Role of metreleptin Ther. Clin. Risk Manag 2015 11 1391 1400 10.2147/TCRM.S66521457725426396524 Search in Google Scholar

[2] Hussain I., Garg A.: Lipodystrophy syndromes. Dermatol. Clin., 2008; 26: 569–578 HussainI. GargA. Lipodystrophy syndromes Dermatol. Clin 2008 26 569 578 10.1016/j.ecl.2016.06.012759023227823605 Search in Google Scholar

[3] Oświęcimska J., Ziora K., Dyduch A.: Lipodystrofia nabyta i wrod-zona. Endokrynol. Otył. Zab. Przem. Mat., 2006; 2: 22–29 OświęcimskaJ. ZioraK. DyduchA. Lipodystrofia nabyta i wrod-zona Endokrynol. Otył. Zab. Przem. Mat 2006 2 22 29 Search in Google Scholar

[4] Brown R.J., Araujo-Vilar D., Cheung P.T., Dunger D., Garg A., Jack M., Mungai L., Oral E.A., Patni N., Rother K.I. i wsp.: The diagnosis and management of lipodystrophy syndromes: A multi-society practice guideline. J. Clin. Endocrinol. Metab., 2016; 101: 4500–4511 BrownR.J. Araujo-VilarD. CheungP.T. DungerD. GargA. JackM. MungaiL. OralE.A. PatniN. RotherK.I. i wsp. The diagnosis and management of lipodystrophy syndromes: A multi-society practice guideline J. Clin. Endocrinol. Metab 2016 101 4500 4511 10.1210/jc.2016-2466515567927710244 Search in Google Scholar

[5] Bar Akinci B., Sahinoz M., Oral E.: Lipodystrophy syndromes: Presentation and treatment. W: Endotext [Internet], red.: K.R. Fe-ingold, B. Anawalt, A. Boyce, G. Chrousos, W.W. de Herder, K. Dhatariya, K. Dungan, A. Grossman, J.M. Hershman, J. Hofland i wsp., South Dartmoiuth (MA) 2018 Bar AkinciB. SahinozM. OralE. Lipodystrophy syndromes: Presentation and treatment W: Endotext [Internet], red Fe-ingoldK.R. AnawaltB. BoyceA. ChrousosG. de HerderW.W. DhatariyaK. DunganK. GrossmanA. HershmanJ.M. J. Hofland i wsp South Dartmoiuth (MA) 2018 Search in Google Scholar

[6] Gonzaga-Jauregui C., Ge W., Staples J., Van Hout C., Yadav A., Colonie R., Leader J.B., Kirchner H.L., Murray M.F., Reid J.G. i wsp.: Clinical and molecular prevalence of lipodystrophy in an unascertained large clinical care cohort. Diabetes, 2020; 69: 249–258 Gonzaga-JaureguiC. GeW. StaplesJ. Van HoutC. YadavA. ColonieR. LeaderJ.B. KirchnerH.L. MurrayM.F. ReidJ.G. i wsp. Clinical and molecular prevalence of lipodystrophy in an unascertained large clinical care cohort Diabetes 2020 69 249 258 10.2337/db19-044731836692 Search in Google Scholar

[7] Araújo-Vilar D., Santini F.: Diagnosis and treatment of lipodystrophy: A step-by-step approach. J. Endocrinol. Invest., 2019; 42: 61–73 Araújo-VilarD. SantiniF. Diagnosis and treatment of lipodystrophy: A step-by-step approach J. Endocrinol. Invest 2019 42 61 73 10.1007/s40618-018-0887-z630418229704234 Search in Google Scholar

[8] Joy T.R., Hegele R.A.: Prevalence of reproductive abnormalities among women with familial partial lipodystrophy. Endocr. Pract., 2008; 14: 1126–1132 JoyT.R. HegeleR.A. Prevalence of reproductive abnormalities among women with familial partial lipodystrophy Endocr. Pract 2008 14 1126 1132 10.4158/EP.14.9.112619158052 Search in Google Scholar

[9] Vantyghem M.C., Vincent-Desplanques D., Defrance-Faivre F., Capeau J., Fermon C., Valat A.S., Lascols O., Hecart A.C., Pigny P., Delemer B. i wsp.: Fertility and obstetrical complications in women with LMNA-related familial partial lipodystrophy. J. Clin. Endocrinol. Metab., 2008; 93: 2223–2229 VantyghemM.C. Vincent-DesplanquesD. Defrance-FaivreF. CapeauJ. FermonC. ValatA.S. LascolsO. HecartA.C. PignyP. DelemerB. i wsp. Fertility and obstetrical complications in women with LMNA-related familial partial lipodystrophy J. Clin. Endocrinol. Metab 2008 93 2223 2229 10.1210/jc.2007-252118364375 Search in Google Scholar

[10] Misra A., Garg A.: Clinical features and metabolic derangements in acquired generalized lipodystrophy Case reports and review of the literature. Medicine, 2003; 82: 129–146 MisraA. GargA. Clinical features and metabolic derangements in acquired generalized lipodystrophy Case reports and review of the literature Medicine 2003 82 129 146 10.1097/00005792-200303000-0000712640189 Search in Google Scholar

[11] Gonzalez-Perez R.R., Lanier V., Newman G.: Leptin’s pro-angiogenic signature in breast cancer. Cancers, 2013; 5: 1140–1162 Gonzalez-PerezR.R. LanierV. NewmanG. Leptin’s pro-angiogenic signature in breast cancer Cancers 2013 5 1140 1162 10.3390/cancers5031140379538324202338 Search in Google Scholar

[12] Karbowska J., Kochan Z.: Leptin as a mediator between obesity and cardiac dysfunction. Postępy Hig. Med. Dośw., 2012; 66: 267–274 KarbowskaJ. KochanZ. Leptin as a mediator between obesity and cardiac dysfunction Postępy Hig. Med. Dośw 2012 66 267 274 10.5604/17322693.99781722706112 Search in Google Scholar

[13] Cammisotto P, Bendayan M.: A review on gastric leptin: The exocrine secretion of a gastric hormone. Anat. Cell Biol., 2012; 45: 1–16 CammisottoP. BendayanM. A review on gastric leptin: The exocrine secretion of a gastric hormone Anat. Cell Biol 2012 45 1 16 10.5115/acb.2012.45.1.1332873622536547 Search in Google Scholar

[14] Denroche H.C., Huynh F.K., Kieffer T.J.: The role of leptin in glucose homeostasis. J. Diabetes Investig., 2012; 3: 115–129 DenrocheH.C. HuynhF.K. KiefferT.J. The role of leptin in glucose homeostasis J. Diabetes Investig 2012 3 115 129 10.1111/j.2040-1124.2012.00203.x402072824843554 Search in Google Scholar

[15] Brannian J.D., Hansen K.A.: Leptin and ovarian folliculogenesis: Implications for ovulation induction and ART outcomes. Semin. Reprod. Med., 2002; 20: 103–112 BrannianJ.D. HansenK.A. Leptin and ovarian folliculogenesis: Implications for ovulation induction and ART outcomes Semin. Reprod. Med 2002 20 103 112 10.1055/s-2002-3250112087495 Search in Google Scholar

[16] Ramos C.F., Zamoner A.: Thyroid hormone and leptin in the testis. Front. Endocrinol., 2014; 5: 198 RamosC.F. ZamonerA. Thyroid hormone and leptin in the testis Front. Endocrinol 2014 5 198 10.3389/fendo.2014.00198424369225505448 Search in Google Scholar

[17] Drugnank. https://go.drugbank.com/drugs/DB09046 Drugnank https://go.drugbank.com/drugs/DB09046 Search in Google Scholar

[18] Musso C., Major M.L., Andres E., Simha V.: Metreleptin treatment in three patients with generalized lipodystrophy. Clin. Med. Insights Case Reports, 2017; 9: 123–127 MussoC. MajorM.L. AndresE. SimhaV. Metreleptin treatment in three patients with generalized lipodystrophy Clin. Med. Insights Case Reports 2017 9 123 127 10.4137/CCRep.S40196521797728096701 Search in Google Scholar

[19] Vasandani C., Clark G.O., Adams-Huet B., Quittner C., Garg A.: Efficacy and safety of metreleptin therapy in patients with type 1 diabetes: A pilot study. Diabetes Care, 2017; 40: 694–697 VasandaniC. ClarkG.O. Adams-HuetB. QuittnerC. GargA. Efficacy and safety of metreleptin therapy in patients with type 1 diabetes: A pilot study Diabetes Care 2017 40 694 697 10.2337/dc16-155328223297 Search in Google Scholar

[20] Agencja Oceny Technologii Medycznych i Taryfikacji: Mya-lept (metreleptyna) we wskazaniu: lipodystrofia Dunningana w przebiegu lipodystrofii o dziedziczeniu dominującym związanej z mutacją w genie LMNA. https://bipold.aotm.gov.pl/assets/files/ zlecenia_mz/2018/212/RPT/212_OT.4311.38.2018_Myalept_lipo-dystrofia.pdf Agencja Oceny Technologii Medycznych i Taryfikacji: Mya-lept (metreleptyna) we wskazaniu: lipodystrofia Dunningana w przebiegu lipodystrofii o dziedziczeniu dominującym związanej z mutacją w genie LMNA https://bipold.aotm.gov.pl/assets/files/ zlecenia_mz/2018/212/RPT/212_OT.4311.38.2018_Myalept_lipo-dystrofia.pdf Search in Google Scholar

[21] Rada Przejrzystości działająca przy Prezesie Agencji Oceny Technologii Medycznych i Taryfikacji: Stanowisko Rady Przejrzystości nr 10/2019 z dnia 28 stycznia 2019 roku w sprawie zasadności wydawania zgód na refundację leku Myalept (metreleptyna) we wskazaniu: lipodystrofia Dunningana w przebiegu lipodystrofii o dziedziczeniu dominującym związanej z mutacją w genie LMNA. https://bipold.aotm.gov.pl/assets/files/zlecenia_mz/2018/212/ SRP/U_4_34_190128_stanowisko_10_Myalept_metreleptyna_import.pdf Rada Przejrzystości działająca przy Prezesie Agencji Oceny Technologii Medycznych i Taryfikacji: Stanowisko Rady Przejrzystości nr 10/2019 z dnia 28 stycznia 2019 roku w sprawie zasadności wydawania zgód na refundację leku Myalept (metreleptyna) we wskazaniu: lipodystrofia Dunningana w przebiegu lipodystrofii o dziedziczeniu dominującym związanej z mutacją w genie LMNA https://bipold.aotm.gov.pl/assets/files/zlecenia_mz/2018/212/SRP/U_4_34_190128_stanowisko_10_Myalept_metreleptyna_import.pdf Search in Google Scholar

[22] Park J.Y., Javor E.D., Cochran E.K., DePaoli A.M., Gorden P.: Long-term efficancy of leptin replacement in patients with Dunnigan-type familial partial lipodystrophy. Metabolism, 2007; 56: 508–516 ParkJ.Y. JavorE.D. CochranE.K. DePaoliA.M. GordenP. Long-term efficancy of leptin replacement in patients with Dunnigan-type familial partial lipodystrophy Metabolism 2007 56 508 516 10.1016/j.metabol.2006.11.010259513617379009 Search in Google Scholar

[23] Simha V., Subramanyam L., Szczepaniak L., Quittner C., Adams-Huet B., Snell P., Garg A.: Comparison of efficacy and safety of leptin replacement therapy in moderately and severely hypolepti-nemic patients with familial partial lipodystrophy of the Dunnigan variety. J. Clin. Endocrinol. Metab., 2012; 97: 785–792 SimhaV. SubramanyamL. SzczepaniakL. QuittnerC. Adams-HuetB. SnellP. GargA. Comparison of efficacy and safety of leptin replacement therapy in moderately and severely hypolepti-nemic patients with familial partial lipodystrophy of the Dunnigan variety J. Clin. Endocrinol. Metab 2012 97 785 792 10.1210/jc.2011-2229331921922170723 Search in Google Scholar

[24] Ajluni N., Dar M., Xu J., Neidert A.H., Oral E.A.: Efficacy and safety of metreleptin in patients with partial lipodystrophy: Lessons from an expanded access program. J. Diabetes Metab., 2016; 7: 659 AjluniN. DarM. XuJ. NeidertA.H. OralE.A. Efficacy and safety of metreleptin in patients with partial lipodystrophy: Lessons from an expanded access program J. Diabetes Metab 2016 7 659 Search in Google Scholar

[25] Vatier C., Fetita S., Boudou P., Tchankou C., Deville L., Riveline J., Young J., Mathivon L., Travert F., Morin D. i wsp.: One-year me-treleptin improves insulin secretion in patients with diabetes linked to genetic lipodystrophic syndromes. Diabetes Obes. Metab., 2016; 18: 693–697 VatierC. FetitaS. BoudouP. TchankouC. DevilleL. RivelineJ. YoungJ. MathivonL. TravertF. MorinD. i wsp. One-year me-treleptin improves insulin secretion in patients with diabetes linked to genetic lipodystrophic syndromes Diabetes Obes. Metab 2016 18 693 697 10.1111/dom.1260626584826 Search in Google Scholar

[26] Araujo-Vilar D., Sánchez-Iglesias S., Guillín-Amarelle C., Castro A., Lage M., Pazos M., Rial J.M., Blasco J., Guillen-Navarro E., Domingo-Jiménez R. i wsp.: Recombinant human leptin treatment in genetic lipodystrophic syndromes: The long-term Spanish experience. Endocrine, 2015; 49: 139–147 Araujo-VilarD. Sánchez-IglesiasS. Guillín-AmarelleC. CastroA. LageM. PazosM. RialJ.M. BlascoJ. Guillen-NavarroE. Domingo-JiménezR. i wsp. Recombinant human leptin treatment in genetic lipodystrophic syndromes: The long-term Spanish experience Endocrine 2015 49 139 147 10.1007/s12020-014-0450-4441264925367549 Search in Google Scholar

[27] Chan J.L., Lutz K., Cochran E., Huang W., Peters Y., Weyer C., Gorden P.: Clinical effects of long-term metreleptin treatment in patients with lipodystrophy Jean. Endocr. Pract., 2011; 17: 922–932 ChanJ.L. LutzK. CochranE. HuangW. PetersY. WeyerC. GordenP. Clinical effects of long-term metreleptin treatment in patients with lipodystrophy Jean Endocr. Pract 2011 17 922 932 10.4158/EP11229.OR349876722068254 Search in Google Scholar

[28] Ravussin E., Smith S.R., Mitchell J.A., Shringarpure R., Shan K., Maier H., Koda J.E., Weyer C.: Enhanced weight loss with pram-lintide/metreleptin: An integrated neurohormonal approach to obesity pharmacotherapy. Obesity, 2009; 17: 1736–1743 RavussinE. SmithS.R. MitchellJ.A. ShringarpureR. ShanK. MaierH. KodaJ.E. WeyerC. Enhanced weight loss with pram-lintide/metreleptin: An integrated neurohormonal approach to obesity pharmacotherapy Obesity 2009 17 1736 1743 10.1038/oby.2009.184275421919521351 Search in Google Scholar